Relay Therapeutics, Inc.
RLAY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.62 | 0.19 | -0.65 | 0.08 |
| FCF Yield | -6.90% | -9.33% | -16.60% | -8.39% |
| EV / EBITDA | -10.47 | -7.39 | -4.68 | -7.34 |
| Quality | ||||
| ROIC | -12.54% | -10.93% | -10.96% | -10.28% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.79 | 0.95 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -31.33% | 107.01% | 86.28% | 93.51% |
| Free Cash Flow Growth | -12.36% | 24.88% | -27.18% | 23.16% |
| Safety | ||||
| Net Debt / EBITDA | 0.72 | 1.15 | 0.55 | 0.91 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -951.07 |